Lead Product(s) : Dexamethasone
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Oculis Completes Phase 3 DIAMOND Trial Enrollment for OCS-01 in DME
Details : OCS-01 (dexamethasone) is a novel, high concentration topical formulation of dexamethasone. It is under phase 3 clinical development for the treatment of Diabetic Macular Edema.
Product Name : OCS-01
Product Type : Steroid
Upfront Cash : Inapplicable
April 10, 2025
Lead Product(s) : Dexamethasone
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dexamethasone
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Oculis Accelerates DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema
Details : OCS-01 (dexamethasone) is a novel, high concentration (15 mg/ml), topical formulation of dexamethasone. It is under phase 3 clinical development for the treatment of Diabetic Macular Edema.
Product Name : OCS-01
Product Type : Steroid
Upfront Cash : Inapplicable
October 21, 2024
Lead Product(s) : Dexamethasone
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ranibizumab
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Roche’s Susvimo Shows Efficacy in Serious Diabetic Eye Conditions
Details : Susvimo (ranibizumab) is a VEGF-A inhibitor, intravitreal implant which is being investigated for the treatment of patients with neovascular diabetic macular edema.
Product Name : Susvimo
Product Type : Antibody
Upfront Cash : Inapplicable
July 18, 2024
Lead Product(s) : Ranibizumab
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Faricimab
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Roche’s Vabysmo Data Show Sustained Retinal Drying and Vision Improvements in RVO
Details : Vabysmo (faricimab) is a vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) inhibitor indicated for the treatment of retinal vein occlusion.
Product Name : Vabysmo
Product Type : Antibody
Upfront Cash : Inapplicable
January 02, 2024
Lead Product(s) : Faricimab
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dexamethasone
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : OCS-01 (dexamethasone) is a novel, high concentration (15 mg/ml), topical formulation of dexamethasone. It is under phase 3 clinical development for the treatment of Diabetic Macular Edema.
Product Name : OCS-01
Product Type : Steroid
Upfront Cash : Inapplicable
December 18, 2023
Lead Product(s) : Dexamethasone
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Faricimab
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Vabysmo (faricimab-svoa) is the first bispecific antibody which targets and inhibits two signalling pathways linked to a number of vision-threatening retinal conditions by neutralising Ang-2 and VEGF-A. It is being investigated for the treatment of retin...
Product Name : Vabysmo
Product Type : Antibody
Upfront Cash : Inapplicable
October 10, 2023
Lead Product(s) : Faricimab
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Faricimab
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Vabysmo (faricimab) is the first bispecific antibody approved for the eye. It targets and inhibits two signalling pathways linked to a number of vision-threatening retinal conditions by neutralising angiopoietin-2 (Ang-2) and vascular endothelial growth ...
Product Name : Vabysmo
Product Type : Antibody
Upfront Cash : Inapplicable
October 02, 2023
Lead Product(s) : Faricimab
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Faricimab
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Accepts Application for Roche’s Vabysmo for The Treatment of Retinal Vein Occlusion (RVO)
Details : Vabysmo (faricimab-svoa) is the first bispecific antibody which targets and inhibits two signalling pathways linked to a number of vision-threatening retinal conditions by neutralising Ang-2 and VEGF-A. It is being investigated for the treatment of retin...
Product Name : Vabysmo
Product Type : Antibody
Upfront Cash : Inapplicable
September 05, 2023
Lead Product(s) : Faricimab
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aflibercept
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sandoz Announces Positive Results from Mylight Phase lll Study for Biosimilar Aflibercept
Details : SOK583A1 (aflibercept) is a recombinant fusion protein that bind to vascular endothelial growth factor A (VEGF-A) and placental growth factor (PlGF) used to treat neovascular (wet) age-related macular degeneration (AMD), various types of macular edema an...
Product Name : Afqlir
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
August 15, 2023
Lead Product(s) : Aflibercept
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dexamethasone
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : OCS-01 eye drops, a novel, once-daily, high concentration, preservative-free, topical OPTIREACH® formulation of dexamethasone is being developed for the treatment of inflammation and pain following ocular surgery.
Product Name : OCS-01
Product Type : Steroid
Upfront Cash : Inapplicable
August 08, 2023
Lead Product(s) : Dexamethasone
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable